bluebird bio (BLUE) Competitors $4.98 0.00 (0.00%) As of 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock BLUE vs. GLSI, TARA, SCPH, LYEL, TNXP, FATE, THTX, ALEC, ACOG, and ENTAShould you be buying bluebird bio stock or one of its competitors? The main competitors of bluebird bio include Greenwich LifeSciences (GLSI), Protara Therapeutics (TARA), scPharmaceuticals (SCPH), Lyell Immunopharma (LYEL), Tonix Pharmaceuticals (TNXP), Fate Therapeutics (FATE), Theratechnologies (THTX), Alector (ALEC), Alpha Cognition (ACOG), and Enanta Pharmaceuticals (ENTA). These companies are all part of the "pharmaceutical products" industry. bluebird bio vs. Greenwich LifeSciences Protara Therapeutics scPharmaceuticals Lyell Immunopharma Tonix Pharmaceuticals Fate Therapeutics Theratechnologies Alector Alpha Cognition Enanta Pharmaceuticals bluebird bio (NASDAQ:BLUE) and Greenwich LifeSciences (NASDAQ:GLSI) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, community ranking, risk, analyst recommendations, media sentiment, dividends, profitability, valuation and earnings. Do institutionals & insiders have more ownership in BLUE or GLSI? 87.4% of bluebird bio shares are owned by institutional investors. Comparatively, 4.2% of Greenwich LifeSciences shares are owned by institutional investors. 1.4% of bluebird bio shares are owned by company insiders. Comparatively, 51.7% of Greenwich LifeSciences shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth. Do analysts prefer BLUE or GLSI? bluebird bio presently has a consensus target price of $44.60, suggesting a potential upside of 795.58%. Greenwich LifeSciences has a consensus target price of $39.00, suggesting a potential upside of 276.45%. Given bluebird bio's higher probable upside, research analysts clearly believe bluebird bio is more favorable than Greenwich LifeSciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score bluebird bio 0 Sell rating(s) 6 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25Greenwich LifeSciences 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has more risk and volatility, BLUE or GLSI? bluebird bio has a beta of 0.27, suggesting that its share price is 73% less volatile than the S&P 500. Comparatively, Greenwich LifeSciences has a beta of 1.74, suggesting that its share price is 74% more volatile than the S&P 500. Does the media refer more to BLUE or GLSI? In the previous week, bluebird bio had 8 more articles in the media than Greenwich LifeSciences. MarketBeat recorded 8 mentions for bluebird bio and 0 mentions for Greenwich LifeSciences. Greenwich LifeSciences' average media sentiment score of 0.00 beat bluebird bio's score of -0.06 indicating that Greenwich LifeSciences is being referred to more favorably in the news media. Company Overall Sentiment bluebird bio Neutral Greenwich LifeSciences Neutral Which has higher earnings and valuation, BLUE or GLSI? Greenwich LifeSciences has lower revenue, but higher earnings than bluebird bio. Greenwich LifeSciences is trading at a lower price-to-earnings ratio than bluebird bio, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratiobluebird bio$83.81M0.58-$211.91M-$41.32-0.12Greenwich LifeSciencesN/AN/A-$8.89M-$1.20-8.63 Is BLUE or GLSI more profitable? Greenwich LifeSciences has a net margin of 0.00% compared to bluebird bio's net margin of -565.74%. Greenwich LifeSciences' return on equity of -185.12% beat bluebird bio's return on equity.Company Net Margins Return on Equity Return on Assets bluebird bio-565.74% -322.46% -53.17% Greenwich LifeSciences N/A -185.12%-164.27% Does the MarketBeat Community prefer BLUE or GLSI? bluebird bio received 1032 more outperform votes than Greenwich LifeSciences when rated by MarketBeat users. Likewise, 70.34% of users gave bluebird bio an outperform vote while only 47.37% of users gave Greenwich LifeSciences an outperform vote. CompanyUnderperformOutperformbluebird bioOutperform Votes104170.34% Underperform Votes43929.66% Greenwich LifeSciencesOutperform Votes947.37% Underperform Votes1052.63% Summarybluebird bio beats Greenwich LifeSciences on 9 of the 17 factors compared between the two stocks. Get bluebird bio News Delivered to You Automatically Sign up to receive the latest news and ratings for BLUE and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BLUE vs. The Competition Export to ExcelMetricbluebird bioBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$48.76M$2.97B$5.44B$8.46BDividend YieldN/A1.72%5.22%4.11%P/E Ratio-0.1331.5627.0120.01Price / Sales0.58430.03394.86118.75Price / CashN/A168.6838.2534.62Price / Book0.143.376.874.60Net Income-$211.91M-$72.17M$3.22B$248.10M7 Day Performance50.45%15.65%5.63%2.88%1 Month Performance20.29%22.18%13.58%15.43%1 Year Performance-75.83%-24.86%18.15%7.74% bluebird bio Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BLUEbluebird bio2.7531 of 5 stars$4.98flat$44.60+795.6%-75.8%$48.76M$83.81M-0.13520GLSIGreenwich LifeSciences1.3452 of 5 stars$9.58+1.6%$39.00+307.1%-27.2%$127.17MN/A-11.973Positive NewsEarnings ReportTARAProtara Therapeutics2.0396 of 5 stars$3.27+0.9%$20.40+523.9%+10.7%$126.15MN/A-1.1630Positive NewsGap UpSCPHscPharmaceuticals4.1737 of 5 stars$2.48+1.6%$14.00+464.5%-25.9%$124.70M$36.33M-1.3130Earnings ReportAnalyst RevisionLYELLyell Immunopharma2.9934 of 5 stars$0.42+5.4%$1.00+137.2%-84.9%$124.52M$61,000.00-0.53270News CoveragePositive NewsEarnings ReportTNXPTonix Pharmaceuticals3.442 of 5 stars$19.19+1.9%$585.00+2,948.5%-95.8%$123.49M$10.09M0.0050Gap UpFATEFate Therapeutics4.3999 of 5 stars$1.07+2.9%$4.60+329.9%-68.7%$122.63M$13.63M-0.65550Earnings ReportGap UpTHTXTheratechnologiesN/A$2.61-0.4%N/A+97.7%$120.01M$88.67M-26.10140ALECAlector3.8206 of 5 stars$1.20+2.6%$4.00+233.3%-76.7%$119.99M$88.34M-0.71270Gap UpACOGAlpha Cognition1.6913 of 5 stars$7.45+0.3%$20.00+168.5%N/A$119.35MN/A-2.91N/AEarnings ReportGap UpENTAEnanta Pharmaceuticals3.8581 of 5 stars$5.55+5.3%$17.25+210.8%-50.9%$118.40M$66.59M-1.12160Positive NewsGap Up Related Companies and Tools Related Companies Greenwich LifeSciences Competitors Protara Therapeutics Competitors scPharmaceuticals Competitors Lyell Immunopharma Competitors Tonix Pharmaceuticals Competitors Fate Therapeutics Competitors Theratechnologies Competitors Alector Competitors Alpha Cognition Competitors Enanta Pharmaceuticals Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:BLUE) was last updated on 5/20/2025 by MarketBeat.com Staff From Our PartnersEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredBanks aren’t ready for this altcoin—are you?While everyone's distracted by Bitcoin's moves, a stealth revolution is underway. One altcoin is quietly po...Crypto 101 Media | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredThis Is The Moment You Betray Trump (Or Prove Them Wrong)They said you wouldn’t last—that Bidenflation, Wall Street selloffs, and DEI funds would break your loyalty to...Colonial Metals | SponsoredHow I profit during chaos…This Guy THRIVES on Chaos Wall Street legend Larry Benedict has thrived through every major market crash. I...Brownstone Research | SponsoredMemorial Day: 59% dividend from Bitcoin (No Crypto Needed)140% Dividends from stocks like Tesla? Discover How for Just $9! For Memorial Day, get the full details of ...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding bluebird bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share bluebird bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy BLUE Stock Free BLUE Stock Alerts